4,203 Shares in Insulet Corporation $PODD Purchased by Focus Partners Advisor Solutions LLC

Focus Partners Advisor Solutions LLC purchased a new stake in shares of Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 4,203 shares of the medical instruments supplier’s stock, valued at approximately $640,000.

Several other institutional investors have also recently added to or reduced their stakes in PODD. Glenmede Investment Management LP grew its stake in Insulet by 1.6% during the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock worth $708,000 after buying an additional 35 shares during the last quarter. Curi Capital LLC increased its stake in shares of Insulet by 0.8% in the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after buying an additional 36 shares during the period. Great Lakes Advisors LLC raised its holdings in Insulet by 1.5% during the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock worth $791,000 after purchasing an additional 40 shares during the last quarter. Camarda Financial Advisors LLC boosted its stake in shares of Insulet by 0.5% in the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after purchasing an additional 40 shares during the last quarter. Finally, Larson Financial Group LLC grew its position in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the period.

Insulet Stock Down 2.5%

Shares of PODD stock opened at $139.70 on Tuesday. The firm has a fifty day moving average of $154.96 and a 200-day moving average of $187.34. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88. The company has a market capitalization of $9.69 billion, a price-to-earnings ratio of 26.11, a P/E/G ratio of 1.13 and a beta of 1.10. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The firm had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The business’s revenue was up 23.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, equities research analysts predict that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Insider Activity at Insulet

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.36% of the stock is currently owned by corporate insiders.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s latest quarterly results exceeded expectations, with earnings of $1.66 per share versus the $1.47 consensus estimate and revenue of $801.7 million versus $787.4 million expected. Revenue increased 23.5% year over year. Why Insulet PODD Stock Is Down Today
• Positive Sentiment: Insulet insiders have predominantly purchased shares during the past six months, including sizable purchases by CEO Ashley McEvoy and other directors. Such buying may signal management confidence following the stock’s decline. Why Insulet PODD Stock Is Down Today
• Neutral Sentiment: Analyst coverage remains generally favorable, with recent Buy-equivalent ratings and a reported median price target of $219.50. However, some recent targets are lower, including $172 from Citigroup and $180 from Evercore ISI, reflecting more cautious near-term expectations. Why Insulet PODD Stock Is Down Today
• Negative Sentiment: The main fundamental concern is Insulet’s softer forward outlook. Lower full-year Omnipod growth guidance and a weaker third-quarter forecast suggest slowing U.S. momentum, overshadowing the earnings and revenue beat. Why Insulet PODD Stock Is Down Today
• Negative Sentiment: Multiple law firms are promoting a securities class action against Insulet and certain executives, alleging investors were harmed by disclosures concerning defective Omnipod manufacturing controls. The allegations have not been proven, but the litigation adds legal, regulatory and reputational risk. The reported lead-plaintiff deadline is August 31, 2026. Insulet Class Action Announcement
• Negative Sentiment: Earlier disclosure of a voluntary correction involving certain Omnipod products, reportedly affecting approximately 7 million Pods and potentially causing insulin under-delivery, continues to raise concerns about manufacturing execution and future costs. Why Insulet PODD Stock Is Down Today

Analyst Ratings Changes

Several brokerages recently weighed in on PODD. The Goldman Sachs Group restated a “buy” rating and issued a $205.00 price objective on shares of Insulet in a report on Wednesday, May 27th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $152.00 target price (down from $275.00) on shares of Insulet in a research report on Thursday, August 6th. Canaccord Genuity Group cut their price target on Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Bank of America reduced their price target on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Finally, Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 price objective (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $195.40.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.